The CTGTAC committee will meet in open session on both days to discuss the toxicity risks of adeno-associated virus (AAV) vector-based gene therapy products. The discussion topics include safety issues identified during preclinical and/or clinical evaluation, and oncogenicity risks due to vector genome integration.
Captioning:
https://www.captionedtext.com/client/event.aspx?EventID=4881213&CustomerID=321
Cellular,Tissue,Therapies
0 Comments